| Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a … J Paavonen, P Naud, J Salmerón, CM Wheeler, SN Chow, D Apter, ... The Lancet 374 (9686), 301-314, 2009 | 2086 | 2009 |
| Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of … J Paavonen, D Jenkins, FX Bosch, P Naud, J Salmerón, CM Wheeler, ... The Lancet 369 (9580), 2161-2170, 2007 | 1696 | 2007 |
| A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection LA Koutsky, KK Holmes, CW Critchlow, CE Stevens, J Paavonen, ... New England journal of medicine 327 (18), 1272-1278, 1992 | 1411 | 1992 |
| Once-daily valacyclovir to reduce the risk of transmission of genital herpes L Corey, A Wald, R Patel, SL Sacks, SK Tyring, T Warren, JM Douglas Jr, ... New England Journal of Medicine 350 (1), 11-20, 2004 | 961 | 2004 |
| Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double … M Lehtinen, J Paavonen, CM Wheeler, U Jaisamrarn, SM Garland, ... The lancet oncology 13 (1), 89-99, 2012 | 903 | 2012 |
| Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined … EA Joura, S Leodolter, M Hernandez-Avila, CM Wheeler, G Perez, ... The Lancet 369 (9574), 1693-1702, 2007 | 855 | 2007 |
| Chlamydia trachomatis: impact on human reproduction J Paavonen, W Eggert-Kruse Human reproduction update 5 (5), 433-447, 1999 | 745 | 1999 |
| High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up LL Villa, RLR Costa, CA Petta, RP Andrade, J Paavonen, OE Iversen, ... British Journal of Cancer 95 (11), 1459-1466, 2006 | 737 | 2006 |
| The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in … DR Brown, SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, ... The Journal of infectious diseases 199 (7), 926-935, 2009 | 706 | 2009 |
| Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma T Anttila, P Saikku, P Koskela, A Bloigu, J Dillner, I Ikäheimo, E Jellum, ... Jama 285 (1), 47-51, 2001 | 659 | 2001 |
| Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis … CM Wheeler, X Castellsagué, SM Garland, A Szarewski, J Paavonen, ... The lancet oncology 13 (1), 100-110, 2012 | 635 | 2012 |
| Pelvic inflammatory disease RC Brunham, SL Gottlieb, J Paavonen New England Journal of Medicine 372 (21), 2039-2048, 2015 | 613 | 2015 |
| Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts … Future I/II Study Group The BMJ 341, 2010 | 550 | 2010 |
| Mucopurulent cervicitis—the ignored counterpart in women of urethritis in men RC Brunham, J Paavonen, CE Stevens, N Kiviat, CC Kuo, CW Critchlow, ... New England journal of medicine 311 (1), 1-6, 1984 | 493 | 1984 |
| Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women N Muñoz, SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, ... Journal of the National Cancer Institute 102 (5), 325-339, 2010 | 481 | 2010 |
| Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up R Hurskainen, J Teperi, P Rissanen, AM Aalto, S Grenman, A Kivelä, ... Jama 291 (12), 1456-1463, 2004 | 474 | 2004 |
| Chlamydia trachomatis infection as a risk factor for invasive cervical cancer P Koskela, T Anttila, T Bjørge, A Brunsvig, J Dillner, M Hakama, ... International journal of cancer 85 (1), 35-39, 2000 | 446 | 2000 |
| Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial R Hurskainen, J Teperi, P Rissanen, AM Aalto, S Grenman, A Kivelä, ... The Lancet 357 (9252), 273-277, 2001 | 440 | 2001 |
| Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data EA Joura, SM Garland, J Paavonen, DG Ferris, G Perez, KA Ault, WK Huh, ... Bmj 344, 2012 | 430 | 2012 |
| A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, CM Wheeler, ... Cancer prevention research 2 (10), 868-878, 2009 | 414 | 2009 |
